Molecular iodine: possible treatment for breast cancer
Symbollon Pharmaceuticals Inc. in Framingham has provided independent scientific publications that show molecular iodine to be a possible treatment for breast cancer, the active agent in Symbollon's drug IoGen.
This research recommends molecular iodine as an adjuvant therapy for breast cancer, and encourages launching human clinical trials testing. Paul Desjourdy, president and CEO of Symbollon noted that the possibility of IoGen being used as a treatment "makes is all the more important that Symbollon expedite the commercialization timeline for IoGen."
Evaluations of rats at the University of Mexico have backed up the treatment. Dr. Carmen Aceves of the dept. of Physiology performed tests on rats, treating one group with molecular iodine and another with iodine. Rats in the molecular iodine group showed a 30% rate of mammary cancer, while the iodine group had a 72.7% rate of mammary cancer.
Recent research has confirmed the effectiveness of molecular iodine, as testing performed at Drexel University showed that molecular iodine alters the gene expression profile in human breast cancer cells.
WBJ Web Partners
Most Recent
0 Comments